-

Kashiv Biosciences Announces Successful Phase 1 Results for Abatacept Biosimilar Candidate, KSHB002

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv Biosciences, LLC, a global leader in biopharmaceutical innovation, today announced that their abatacept biosimilar candidate, KSHB002, has successfully met the primary endpoints in its Phase 1 clinical trial. The trial demonstrated pharmacokinetic equivalence to the US-licensed and EU-authorized reference product, ORENCIA®.

KSHB002, a 125 mg/mL pre-filled syringe injection, was evaluated in a randomized, open-label study involving 300 healthy male and female adults. The study was designed with three parallel arms and assessed the pharmacokinetics, safety, and immunogenicity of KSHB002 compared to the reference product. All participants received a single subcutaneous dose.

The results demonstrated that both primary endpoints, maximum serum concentration (Cmax) and area under the concentration-time curve from time zero to infinity (AUC₀–∞), were within the 80-125% bioequivalence range, confirming pharmacokinetic equivalence. Furthermore, the safety and immunogenicity profiles of KSHB002 were comparable to those of ORENCIA®.

Kashiv Biosciences is developing the proposed abatacept biosimilar as both subcutaneous and intravenous formulations.

“We are thrilled with the results of our Phase 1 study and are excited to move forward with our global Phase 3 efficacy and safety trial. This represents a pivotal step in advancing the evaluation of KSHB002 for patients with rheumatoid arthritis,” stated Dr. Sandeep Athalye, CEO of Kashiv Biosciences.

About Kashiv Biosciences:

Kashiv Biosciences, LLC is a vertically integrated biopharmaceutical company with a diverse portfolio of commercial and advanced clinical-stage assets. Operating in the United States and India, Kashiv Biosciences leverages robust infrastructure and highly skilled teams to deliver global R&D, clinical, manufacturing, regulatory, and IP capabilities. Our mission is to advance patient care and improve access to affordable essential medicines.

Contacts

Dr. Paras Vasanani
paras.vasanani@kashivbio.com
www.kashivbiosciences.com

Industry:

Kashiv Biosciences, LLC

Release Versions
English

Contacts

Dr. Paras Vasanani
paras.vasanani@kashivbio.com
www.kashivbiosciences.com

More News From Kashiv Biosciences, LLC

Kashiv BioSciences Announces Validation and Acceptance of Market Authorization Application by Health Canada for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced that Health Canada has validated and accepted the marketing authorization application (MAA) for ADL-018, the Company’s proposed biosimilar for XOLAIR® (omalizumab). Omalizumab, a humanized monoclonal antibody that targets free IgE, is indicated for the treatment of moderate to severe persistent asthma (6 years and older patients), chronic rhinosinusitis with...

Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”). The transaction is subject to approval by Amneal shareholders, receipt of regulatory approvals and satisfaction of customary closing conditions and is expected to close in the second half of 2026. This acquisition combines Kashiv’s extensive expertise in the development and manufacturing o...

Kashiv BioSciences Strengthens Executive Leadership with New Chief Operating Officer and Senior Vice President of Regulatory Affairs

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced the appointment of Viet Nguyen as Chief Operating Officer and Arlene Wolny as Senior Vice President of Regulatory Affairs. Both leaders will be based in Piscataway, New Jersey. Viet Nguyen has over two decades of leadership experience, with deep expertise in building high-performing teams, scaling complex operations, and driving commercial readiness across mu...
Back to Newsroom